达格列净治疗非活动性狼疮肾炎:随机交叉试验
BACKGROUND: Lupus nephritis (LN) patients under immunosuppression were excluded from the main trials with sodium-glucose co-transporter 2 inhibitors. This trial aims to analyse the effect and safety of dapagliflozin in inactive LN patients with residual proteinuria.…
要点
- 非活动性狼疮肾炎伴残余蛋白尿患者加用达格列净6个月,蛋白尿降低36.1%。
- 达格列净组低血压症状报告7例(33.3%),但无停药且血压体重无显著变化。
核心结论
- 在非活动性狼疮肾炎伴残余蛋白尿患者中,达格列净可显著降低蛋白尿且未发现安全性担忧。
研究设计与样本
- 患者随机接受达格列净联合标准治疗或仅标准治疗6个月后交叉。
主要发现
- 达格列净组报告低血压症状7例(33.3%),但无停药,随访期间组间血压和体重无显著变化。
- 每组各报告1例尿路感染,但为同一患者。
关键数值与推荐
- 纳入标准:成人狼疮肾炎(III型、IV型±V型)无活动性,蛋白尿>500 mg/24 h,eGFR≥20 ml/min。
- 维持治疗需稳定使用RAAS抑制剂和吗替麦考酚酯≤2 g/天。
临床怎么用
- 对于非活动性狼疮肾炎伴残余蛋白尿且eGFR≥20 ml/min的患者,可考虑在标准治疗基础上加用达格列净以降低蛋白尿。
- 使用达格列净时需关注低血压症状,但本试验中未导致停药。
局限性
- 随访时间较短(6个月交叉),长期肾脏结局未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lupus nephritis (LN) patients under immunosuppression were excluded from the main trials with sodium-glucose co-transporter 2 inhibitors. This trial aims to analyse the effect and safety of dapagliflozin in inactive LN patients with residual proteinuria. METHODS: We recruited adult LN patients (class III, IV(±V)] without activity, with proteinuria >500 mg/24 h and an estimated glomerular filtration rate (eGFR) ≥20 ml/min, on maintenance treatment with stable renin-angiotensin-aldosterone system inhibitors and mycophenolate mofetil ≤2 g/day. They were randomized to receive dapagliflozin on top of standard-of-care (SoC) therapy or not. After 6 months the groups were crossed over. The primary endpoint is a reduction of proteinuria compared with baseline (6 and 12 months). RESULTS: From 97 screened patients, we excluded 67 due to active LN, low proteinuria or low eGFR. Thirty patients were randomized: 14 to start the treatment with dapagliflozin on top of SoC therapy and 16 to remain with the usual therapy for 6 months. Nine patients were excluded from the analysis due to new LN flares or lost to follow-up. The mean age was 40.6 ± 12.3 years, 19 (90.5%) were female, none had diabetes and the mean body mass index was 26.1 ± 5.2. The final analysis showed a significant reduction in proteinuria of -36.1% in patients after 6 months of dapagliflozin as opposed to -3.5% for those in the SoC therapy group (P = .03). There were more reported hypotension symptoms in the dapagliflozin group [7 cases (33.3%)] but no drug withdrawal and no significant changes in blood pressure or weight in the follow-up between the groups. There was one case of urinary infection in each group, but in the same patient. CONCLUSIONS: We demonstrate a significant reduction in residual proteinuria in patients with inactive LN with dapagliflozin without safety concerns.
引用
- Vajgel G, Júnior BMDS, Filho CRSM, et al. Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial. Nephrol Dial Transplant. 2026. PMID: 41324239. doi:10.1093/ndt/gfaf257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。